sanofi

Sanofi names senior VP of global services

Monday, August 1, 2011 12:22 PM

Sanofi has named Greg Irace, currently president and CEO of Sanofi's US operations, its senior vice president, global services, a newly created role. He will lead the global information systems function, be responsible for shared support functions across all Sanofi businesses in North America and play a key role in the development of a global strategy for shared services. Irace will continue to be a member of the Global Management Committee. He will be based in Bridgewater, New Jersey.

More... »

FDA, EMA reviewing Sanofi’s Multaq

Monday, July 25, 2011 01:54 PM

U.S. drug regulators are reviewing data from a halted clinical trial of Sanofi's key heart drug Multaq to determine how it may affect patients taking it for approved indications, according to Reuters.

More... »

Venture capital funding for biotech soars 46%

Wednesday, July 20, 2011 01:52 PM

Venture capital funding in biotechnology companies jumped 46% in the second quarter, as investors looked to replenish their portfolios after an increase in acquisitions and initial public offerings, according to Bloomberg News.

More... »

EMD Serono names Hoyes president

Wednesday, July 20, 2011 11:33 AM

EMD Serono, an affiliate of Germany-based Merck, has named James Hoyes president. He will be responsible for driving the strategic direction of the U.S. commercial organization as well as managing the day-to-day business of the U.S. affiliate of Merck. Hoyes will also serve as a member of the executive management board for Merck Serono, the global pharmaceuticals division of Merck.

More... »

Sanofi, Regeneron announce trial results

Friday, July 15, 2011 10:19 AM

Sanofi and Regeneron Pharmaceuticals announced results from phase IIb trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R).

More... »

ZALTRAP trial recommended for advancement

Friday, July 8, 2011 12:58 PM

Regeneron Pharmaceuticals has announced that its phase III VENICE clinical trial evaluating the investigational agent ZALTRAP (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns.  This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

More... »

Merck Serono changes R&D organizational structure

Thursday, July 7, 2011 02:02 PM

Merck Serono, a division of Merck of Darmstadt, Germany, is putting a new organizational structure for research and development into effect. Two dedicated groups, focusing on different stages of pharmaceutical innovation (pre- and post- proof-of-concept), will be created as a first step in redesigning Merck Serono's R&D model.

More... »

Sanofi collaborates with Rib-X Pharmaceuticals

Thursday, July 7, 2011 01:10 PM

Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics, according to InPharm.

More... »

Genticel names Dr. Hoch to supervisory board

Wednesday, July 6, 2011 10:21 AM

Genticel, a clinical biopharmaceutical company developing vaccines for human papillomavirus (HPV), has appointed Dr. Didier Hoch to the company’s supervisory board.

More... »

Radvanyi joins Genesis Biopharma

Wednesday, July 6, 2011 10:19 AM

Genesis Biopharma, a biotechnology company developing targeted cancer therapies, has named Laszlo Radvanyi, Ph.D., to its Scientific and Medical Advisory Board.

More... »